Analyst firms · Raymond James · IFRX

Raymond James IFRX price target and rating history

InflaRx N.V. (IFRX) · Health Care

Raymond James rates InflaRx N.V. (IFRX) Strong Buy with a $9 price target, as of its latest action on May 13, 2026. It has published 5 rating actions on IFRX since August 2021, including 2 upgrades and 1 downgrade. Across 4 firms with a IFRX price target in the last 12 months, the median target is $6.50. Raymond James's $9 is 38% above that.

Current rating
Strong Buy
Price target
$9
Median target, all firms
$6.50
Actions on IFRX
5

Raymond James price target on IFRX

$15$8.50$220222023202420252026
Raymond James price target on IFRX, each point a stated target, August 2021 to May 2026.

Every Raymond James rating on IFRX

How other firms rate IFRX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
NeedhamBuy$8Sep 14, 2026
Raymond JamesStrong Buy$9May 13, 2026
OppenheimerOutperform$5Apr 24, 2026
Leerink PartnersMarket Perform$2Dec 3, 2025

Questions about Raymond James and IFRX

What is Raymond James's price target for IFRX?
Raymond James's latest stated price target for InflaRx N.V. (IFRX) is $9, from its action on May 13, 2026.
What is Raymond James's rating on IFRX?
Raymond James rates IFRX Strong Buy, a bullish rating, as of May 13, 2026.
When did Raymond James last change its view on IFRX?
On May 13, 2026, Raymond James upgrades to Strong Buy from Outperform, price target $9.
How does Raymond James's IFRX target compare with other analysts?
Across 4 firms with a IFRX price target in the last 12 months, the median target is $6.50. Raymond James's $9 is 38% above that.

All Raymond James ratingsIFRX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.